메모리 지원 시스템 타당성 조사
메모리 지원 시스템 구현: 타당성 조사
The purpose of this study is to determining the feasibility of providing the Memory Support System (MSS) to individuals with mild cognitive impairment (MCI) and their partners at a clinic in Ontario, Canada. This will involve a) collecting information from patients referred to the a memory clinic and geriatric day hospital about the patient's interest in and the patient's preferred method to administer the MSS; and b) a cost analysis related to implementation of the MSS. The study will also measure efficacy outcomes of the MSS regarding program adherence as well as to self-reported IADLs, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden among a sample of individuals with MCI and their care partners
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
A survey will be created and sent out to participants with MCI who have expressed interest in participating in research and have been seen at a memory clinic or geriatric day hospital after the initiation of the study. The survey will consist of a Likert scale and open questions related to patient interest in and preferred length of MSS administration and preference for in-person versus virtual administration.
During and after collection of the survey data, a sample of 20 individuals with MCI (ages ≥50) and their care partners will undergo MSS training.
At enrollment in the MSS training, participants with MCI and their care partners will complete measures of cognitive and functional status. Participants and partners will also complete measures of treatment adherence, IADLs, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden at baseline, treatment end, and 8-week follow-up. Participants will complete the MSS training consisting of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after initial assessment. Training will be offered in English or French. After the intervention, participants and their partners will complete a semi-structured interview, seeking suggestions for improving the MSS, teaching curriculum, and intervention logistics.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Neil Thomas, MD
- 전화번호: 613-562-6322
- 이메일: nthomas@bruyere.org
연구 연락처 백업
- 이름: Nayna Kirubakar
- 전화번호: 1266 613-562-6262
- 이메일: nkirubakar@bruyere.org
연구 장소
-
-
Ontario
-
Ottawa, Ontario, 캐나다, K1H 5C8
- 모병
- Bruyère Health Research Institute
-
연락하다:
- Neil Thomas, MD
- 전화번호: 613-562-6322
- 이메일: nthomas@bruyere.org
-
연락하다:
- Nayna Kirubakar
- 전화번호: 1266 613-562-6262
- 이메일: nkirubakar@bruyere.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- diagnosis of single or multi-domain MCI
- Clinical Dementia Rating global (CDR) score of ≤ 0.5
- Montreal Cognitive Assessment score of ≥18
- available contact with a care partner ≥ 2 times weekly
- absence or stable intake of nootropic(s) for ≥ 3 months
Exclusion Criteria:
- visual/hearing impairment and/or history of reading or written inability/disability sufficient to interfere with MSS training
- concurrent participation in another related clinical trial
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 메모리 지원 시스템 참가자
|
The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Interest in completion of MSS training
기간: From study start date up to 19 months.
|
Percentage of participants that complete the feasibility survey and agree or strongly agree with the statement that they are interested in completing MSS training. |
From study start date up to 19 months.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adherence to French Memory Support System Intervention
기간: One week after starting the treatment (MSS intervention), at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from adherence scores from one week after starting treatment (MSS intervention) at treatment end and at 8 weeks after the treatment end. Using an adherence scale from 0 to 10, with 10 being highest and a cut-off score of ≥ 7 points suggesting adherence with the MSS. |
One week after starting the treatment (MSS intervention), at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Center for Epidemiologic Studies Depression Scale
기간: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Depression screening scale using Likert scale. Total score of 0-60 points, with higher scores signifying a worse outcome (higher levels of depression). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Everyday Cognition questionnaire.
기간: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report measure of performance based instrumental activities of daily living. Total score of 23-92, with higher scores indicating a worse outcome. |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Functional Assessment Questionnaire
기간: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based report of performance of instrumental activities of daily living. Total score of 0-30, with higher scores indicating a worse outcome (higher level of dependence). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Quality of Life in Alzheimer Disease
기간: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report quality of life scale. Total score of 13-52, with higher scores indicating a better outcome (better quality of life). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
State-Trait Anxiety Inventory by the Resources for Enhancing Alzheimer's Caregiver Health project
기간: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report anxiety scale. Total score of 10-40 with higher scores indicating a worse outcome (higher level of anxiety). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Chronic Disease Self-efficacy Scale
기간: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Selected questions related to memory and cognition from self report scale. Total score of 9-90 with higher scores indicating a better outcomes (higher feeling of self-efficacy). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Caregiver Burden Inventory Short-Form
기간: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based scale of level of caregiver burden. Total score of 0-48 with higher scores indicating a worse outcome (higher level of burden). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Neil Thomas, MD, Bruyère Health Research Institute.
- 수석 연구원: Octavio Santos, PhD, Ottawa Hospital Research Institute, Bruyère Health Research Institute
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- M16-23-024
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
De-identified data from the study may be shared with other researchers within the HABIT consortium. Data that may be shared will include the results of the feasibility survey and the scores from the baseline, treatment end and 8 week follow up outcome measures collected from participants who complete MSS training.
IPD 공유 기간
Data will be available after the end date of the study and kept indefinitely.
IPD 공유 액세스 기준
Upon request that is approved by the study principal investigators.
IPD 공유 지원 정보 유형
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .